Department of Mental Health and Addiction, University of Milan, ASST Fatebenefratelli-Sacco, Milan, Italy.
"Aldo Ravelli" Center for Nanotechnology and Neurostimulation, University of Milan, Milan, Italy.
Curr Neuropharmacol. 2023;21(11):2206-2216. doi: 10.2174/1570159X21666230719162023.
Schizophrenia is a psychiatric disorder whose therapeutic objectives are aimed at reducing symptoms and improving patient's quality of life. First- and second-generation antipsychotics present numerous side effects. Recently introduced in the treatment of schizophrenia, cariprazine has shown to improve positive and negative symptoms as well as cognitive impairment, with good tolerability.
To assess the level of consensus among Italian psychiatrists in relation to the use of cariprazine in the treatment of schizophrenia by using the Delphi technique.
A Delphi study was undertaken between January and July 2022. Two questionnaires were consecutively sent to a panel of 97 psychiatrists from all over Italy, of which 81 actively participated, anonymously, in at least one of the two consultations with a sufficiently high response rate (83%).
Broad consensus in terms of the efficacy and safety of cariprazine in the treatment of schizophrenia during all phases of the disorder. The young first-episode schizophrenia patient with or without substance abuse seems to be an excellent candidate for cariprazine therapy. In addition, the lack of side effects makes cariprazine a suitable drug for adult and elderly patients with schizophrenia. However, there is still limited experience with the use of cariprazine, along with little knowledge of the most recent real-life data.
These results could encourage wider dissemination of evidence-based practices with the final aim of optimizing the clinical use of cariprazine in patients with schizophrenia.
精神分裂症是一种精神疾病，其治疗目标旨在减轻症状并提高患者的生活质量。第一代和第二代抗精神病药物存在许多副作用。最近引入精神分裂症治疗的卡利拉嗪已被证明可改善阳性和阴性症状以及认知障碍，具有良好的耐受性。
使用德尔菲技术评估意大利精神科医生在使用卡利拉嗪治疗精神分裂症方面的共识程度。
在 2022 年 1 月至 7 月期间进行了一项德尔菲研究。向来自意大利各地的 97 名精神科医生小组连续发送了两份问卷，其中 81 名精神科医生以匿名方式积极参与了至少一次两次咨询中的一次，且应答率足够高（83%）。
在疾病的所有阶段，卡利拉嗪治疗精神分裂症的疗效和安全性方面存在广泛共识。伴有或不伴有物质滥用的首发精神分裂症年轻患者似乎是卡利拉嗪治疗的极佳人选。此外，由于缺乏副作用，卡利拉嗪是适合患有精神分裂症的成年和老年患者的药物。然而，卡利拉嗪的使用经验仍然有限，并且对最近的实际数据了解甚少。
这些结果可能会鼓励更广泛地传播基于证据的实践，最终目的是优化卡利拉嗪在精神分裂症患者中的临床应用。
